Core Insights - The AI Fund Guotou Ruijin Healthcare Mixed A (000523) reported a profit of 7.8014 million yuan for Q2 2025, with a weighted average profit per fund share of 0.0565 yuan [2] - The fund's net value growth rate for the reporting period was 6.53%, and as of the end of Q2, the fund size was 121 million yuan [2] - The fund focuses on flexible allocation, primarily investing in pharmaceutical and healthcare stocks, with a unit net value of 1.004 yuan as of July 17 [2] Fund Performance - As of July 17, the fund's one-year cumulative net value growth rate was 31.01%, ranking 86 out of 133 comparable funds [3] - The fund's three-month cumulative net value growth rate was 15.57%, ranking 106 out of 138 comparable funds [3] - The fund's three-year cumulative net value growth rate was -12.05%, ranking 69 out of 106 comparable funds [3] Risk Metrics - The fund's three-year Sharpe ratio was -0.0788, ranking 71 out of 105 comparable funds [9] - The maximum drawdown over the past three years was 41.28%, with the largest single-quarter drawdown occurring in Q3 2022 at 29.67% [11] Investment Strategy - The fund manager indicated a continued increase in investment in the innovative drug sector, focusing on companies with high probability of business development (BD) and those with low expectations for BD in their valuations [2] - The fund maintains a significant allocation to non-innovative drug sectors, including research services, CXO, and medical devices [2] Fund Holdings - As of June 30, the fund's top ten holdings included companies such as Heng Rui Pharmaceutical, Kelun Pharmaceutical, and Zai Lab [19] - The average stock position over the past three years was 90.54%, compared to the industry average of 86.87% [14]
国投瑞银医疗保健混合A：2025年第二季度利润780.14万元 净值增长率6.53%
Sou Hu Cai Jing·2025-07-18 02:38